LAG3 and melanoma: The higher level of LAG-3+ T cells in the blood of patients with advanced melanoma compared to patients with resected melanoma tumors suggested that there were more T cells with a relatlimab ‘target’ in the advanced setting than in the resected disease setting, which may have been driven by the presence of tumor.